Zenocutuzumab MCLA-128; PB4188; R040517|cas:1969309-56-5|西域试剂

Zenocutuzumab MCLA-128; PB4188; R040517

产品编号：Bellancom-P99507| CAS NO：1969309-56-5

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P99507	￥3300.00	杭州北京（现货）
Bellancom-P99507	￥8500.00	杭州北京（现货）
Bellancom-P99507	￥13600.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Zenocutuzumab MCLA-128; PB4188; R040517

产品介绍

Zenocutuzumab (MCLA-128) 是一种双特异性人源化 IgG1 抗体，包含两个不同的 Fab 臂，靶向 HER2 和 HER3 的细胞外结构域。

生物活性

Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3.

体外研究

Zenocutuzumab（0.001-1000 nM；96 小时）抑制肺癌和乳腺癌细胞系的细胞生长。
Zenocutuzumab（0.1-1000 nM；24 小时）抑制 HER3 和 AKT 磷酸化，在肺癌和乳腺癌细胞系中诱导细胞凋亡和细胞周期停滞的标志物。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	Human bronchiolar epithelial cell lines (HBEC)
Concentration:	0.001 nM, 0.01 nM, 0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM
Incubation Time:	96 h
Result:	Reduced the growth of isogenic HBEC expressing either CD74-NRG1 or VAMP2-NRG1 fusions.

Western Blot Analysis

Cell Line:	HBEC-CD74-NRG1, LUAD-0061AS3, MDA-MB-175-VII cells
Concentration:	0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM
Incubation Time:	24 hours
Result:	Inhibited HER3, STAT3, AKT, p70S6K, and S6 phosphorylation.

体内研究
(In Vivo)

Zenocutuzumab（2.5-25 mg/kg；腹腔注射；每周一次；持续 28 天）导致生长显着减少，包括肿瘤消退。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6 to 12-week-old female NSG™ (LUAD-0061AS3), BALB/c nude (OV-10–0050) or athymic nude (ST2891, ST3204 and CTG-0953) mice injected with NRG1 fusion-positive patient-derived xenograft (PDX) tumors.
Dosage:	2.5 mg/kg, 8 mg/kg, or 25 mg/kg
Administration:	i.p.; once weekly; for 28 days
Result:	Blocked growth of lung and ovarian cancer PDX models.

体内研究

Zenocutuzumab（2.5-25 mg/kg；腹腔注射；每周一次；持续 28 天）导致生长显着减少，包括肿瘤消退。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6 to 12-week-old female NSG™ (LUAD-0061AS3), BALB/c nude (OV-10–0050) or athymic nude (ST2891, ST3204 and CTG-0953) mice injected with NRG1 fusion-positive patient-derived xenograft (PDX) tumors.
Dosage:	2.5 mg/kg, 8 mg/kg, or 25 mg/kg
Administration:	i.p.; once weekly; for 28 days
Result:	Blocked growth of lung and ovarian cancer PDX models.

体内研究

Zenocutuzumab（2.5-25 mg/kg；腹腔注射；每周一次；持续 28 天）导致生长显着减少，包括肿瘤消退。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6 to 12-week-old female NSG™ (LUAD-0061AS3), BALB/c nude (OV-10–0050) or athymic nude (ST2891, ST3204 and CTG-0953) mice injected with NRG1 fusion-positive patient-derived xenograft (PDX) tumors.
Dosage:	2.5 mg/kg, 8 mg/kg, or 25 mg/kg
Administration:	i.p.; once weekly; for 28 days
Result:	Blocked growth of lung and ovarian cancer PDX models.